Effects of high dose angiotensin II receptor blocker or combination of angiotensin II and calcium channel blocker on ambultory blood pressure in patients with hypertension and type 2 diabetes (randomized controlled clinical trial)

Effects of high dose angiotensin II receptor blocker or combination of angiotensin II and calcium channel blocker on ambultory blood pressure in patients with hypertension and type 2 diabetes (randomized controlled clinical trial) - Effects of high dose angiotensin II receptor blocker or combination of angiotensin II and calcium channel blocker on ambultory blood pressure in patients with hypertension and type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020632

Enrollment

110

Registered

2016-01-20

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension with type 2 diabetes mellitus

Interventions

Olmesartan medoxomil 40 mg daily Olmesartan medoxomil 20 mg plus azelnidipine 16 mg daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) hypertension (2) age >= 20 (3) type 2 diabetes

Exclusion criteria

Exclusion criteria: (1) secondary hypertension (2) past histody of cardiovascular disease (3) resistant hypertension (4) inadequacy for this therapy (5) severe renal dysfunction (eGFR < 45 mL/min/1.73m2) (6) severe liver dysfunction (Child-Pugh: class B or C) (7) having malignancy or collagen disease (8) chronic Af (9) pregnancy or lactation in women (10) history of allergy for olmesartan medoxomil or azelnidipine

Design outcomes

Primary

Measure	Time frame
The change in ambulatory blood pressure (nighttime SBP) between baseline and after 12 weeks of treatment	—

Countries

Japan

Contacts

Public ContactMotohiro Shimizu

Kyushu University Hospital Department of General Internal Medicine

smotohir@gim.med.kyushu-u.ac.jp092-642-5909

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026